news
Single step antibody capture and clarification for intensified bioprocesses
Research shows magnetic beads coupled with protein A can clarify very high cell concentrations and capture antibodies with high efficiency in a single step.
List view / Grid view
R&D
news
Phase III clinical trial for respiratory syncytial virus (RSV) vaccine begins
Pfizer’s RENOIR Phase III trial will evaluate the efficacy, immunogenicity and safety of their respiratory syncytial virus (RSV) vaccine.
news
Fostamatinib reduces COVID-19 risks by 50 percent in Phase II study
Fostamatinib significantly reduced serious adverse effects and risk of death in hospitalised COVID-19 patients, shows Phase II study.
news
HIV vaccine fails to protect women against infection
The investigational vaccine tested in sub-Saharan Africa posed no safety concerns but did not provide sufficient HIV protection.
news
NICE approves inclisiran for LDL cholesterol reduction
The UK approval follows a Phase III study in which Leqvio® (inclisiran) reduced low-density lipoprotein cholesterol (LDL-C) by 55 percent.
news
Dupixent® reduces atopic dermatitis by 70 percent in Phase III trial
Dupixent is the first biologic medicine to significantly reduce signs and symptoms of atopic dermatitis in children as young as six months.
news
CPI launches RNA Centre of Excellence and training academy
CPI have launched an RNA Centre of Excellence in Darlington to boost development, scale-up and manufacture of RNA therapies and vaccines.
whitepaper
Application note: USP <643> TOC limit changes
This application note addresses the TOC limit changes in USP for packaged water. The new limits account for varying container volumes.
news
Raman spectroscopy for nasal suspension characterisation
Researchers show that combining morphologically-directed Raman spectroscopy (MDRS) with dissolution analysis allows for particle size analysis in fully formulated nasal suspension sprays.
news
Jardiance® displays 21 percent risk reduction in heart failure patients
Jardiance displayed a 21 percent risk reduction in adults with heart failure with preserved ejection fraction in Phase III study.
article
‘Magic bullets’ for all: democratising biologics by rethinking antibody development, manufacturing and delivery
Antibody therapeutics revolutionised how diseases like cancer are treated in the developed world, but their high manufacturing cost and cumbersome distribution and administration leave them out of reach for most. In this guest article, Lumen Bioscience’s CEO, Brian Finrow, and EVP of Production & Development, Craig Behnke, discuss how new…
article
UK life sciences sector: do you have the Vision for innovation?
Here, EPR explores some highlights of the UK’s new Life Sciences Vision for the pharma, biopharma and biotech industries, covering topics from funding to regulatory reviews and clinical trial innovation.
news
A Raman spectroscopy technique to reliably analyse hydrogels
Scientists show how a combined time-resolved Raman and fluorescence spectroscopy can be applied to provide reliable drug diffusion data for drug-hydrogel combinations.
news
Increase in virtual trials improves patient accrual rates, finds report
The increased use of virtual components in clinical trials has led to fewer trial delays or terminations due to low participant numbers.
news
Vaxneuvance™ meets immunogenicity and safety endpoints in Phase III trial
Merck announces positive results from a Phase III study evaluating Vaxneuvance™ against a pneumococcal conjugate vaccine in infants.
